KR20100018523A - ＣＲＩｇ 길항제 - Google Patents

ＣＲＩｇ 길항제 Download PDF

Info

Publication number
KR20100018523A
KR20100018523A KR1020097024920A KR20097024920A KR20100018523A KR 20100018523 A KR20100018523 A KR 20100018523A KR 1020097024920 A KR1020097024920 A KR 1020097024920A KR 20097024920 A KR20097024920 A KR 20097024920A KR 20100018523 A KR20100018523 A KR 20100018523A
Authority
KR
South Korea
Prior art keywords
crig
antibody
thr
leu
antagonist
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020097024920A
Other languages
English (en)
Korean (ko)
Inventor
멘노 반 로케렌 캄파뉴
Original Assignee
제넨테크, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39645433&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR20100018523(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 제넨테크, 인크. filed Critical 제넨테크, 인크.
Publication of KR20100018523A publication Critical patent/KR20100018523A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020097024920A 2007-05-01 2008-04-25 ＣＲＩｇ 길항제 Withdrawn KR20100018523A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US91534007P 2007-05-01 2007-05-01
US60/915,340 2007-05-01

Publications (1)

Publication Number Publication Date
KR20100018523A true KR20100018523A (ko) 2010-02-17

Family

ID=39645433

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020097024920A Withdrawn KR20100018523A (ko) 2007-05-01 2008-04-25 ＣＲＩｇ 길항제

Country Status (16)

Country Link
US (1) US20090162356A1 (enExample)
EP (1) EP2152749A1 (enExample)
JP (1) JP2010526076A (enExample)
KR (1) KR20100018523A (enExample)
CN (1) CN101675078A (enExample)
AR (1) AR066375A1 (enExample)
AU (1) AU2008247958A1 (enExample)
BR (1) BRPI0810926A2 (enExample)
CA (1) CA2682835A1 (enExample)
CL (1) CL2008001238A1 (enExample)
IL (1) IL201165A0 (enExample)
MX (1) MX2009011407A (enExample)
PE (1) PE20090239A1 (enExample)
RU (1) RU2009144280A (enExample)
WO (1) WO2008137338A1 (enExample)
ZA (1) ZA200906812B (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080124355A1 (en) 2006-09-22 2008-05-29 David Gordon Bermudes Live bacterial vaccines for viral infection prophylaxis or treatment
SG190596A1 (en) 2008-05-06 2013-06-28 Genentech Inc Affinity matured crig variants
US8241623B1 (en) 2009-02-09 2012-08-14 David Bermudes Protease sensitivity expression system
US8771669B1 (en) 2010-02-09 2014-07-08 David Gordon Bermudes Immunization and/or treatment of parasites and infectious agents by live bacteria
US9597379B1 (en) 2010-02-09 2017-03-21 David Gordon Bermudes Protease inhibitor combination with therapeutic proteins including antibodies
US8524220B1 (en) 2010-02-09 2013-09-03 David Gordon Bermudes Protease inhibitor: protease sensitivity expression system composition and methods improving the therapeutic activity and specificity of proteins delivered by bacteria
US9593339B1 (en) 2013-02-14 2017-03-14 David Gordon Bermudes Bacteria carrying bacteriophage and protease inhibitors for the treatment of disorders and methods of treatment
CN104231085B (zh) * 2013-09-05 2017-03-15 复旦大学附属肿瘤医院 靶向特异性补体系统抑制剂、其制备方法及应用
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
CN105924515B (zh) * 2016-04-25 2019-06-14 中国人民解放军第三军医大学 免疫共刺激分子vsig4激活性表位肽、单克隆抗体及其制备方法和应用
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
CN110944666B (zh) 2017-06-26 2024-12-31 博奥泰克尼公司 杂交瘤克隆、vsig-4的单克隆抗体，以及制备和使用的方法
EP3873929A4 (en) * 2018-09-28 2022-11-23 Eutilex Co., Ltd. ANTI-HUMAN VSIG4 ANTIBODIES AND USES THEREOF
WO2020236626A1 (en) * 2019-05-17 2020-11-26 Herzlinger George A Methods and systems for treating microbial disease
CA3150807A1 (en) * 2019-09-04 2021-03-11 Y-Biologics Inc. Anti-vsig4 antibody or antigen binding fragment and uses thereof
WO2022184853A1 (en) 2021-03-03 2022-09-09 Pierre Fabre Medicament Anti-vsig4 antibody or antigen binding fragment and uses thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8088386B2 (en) * 1998-03-20 2012-01-03 Genentech, Inc. Treatment of complement-associated disorders

Also Published As

Publication number Publication date
AR066375A1 (es) 2009-08-12
PE20090239A1 (es) 2009-03-19
BRPI0810926A2 (pt) 2014-11-04
RU2009144280A (ru) 2011-06-10
MX2009011407A (es) 2009-11-05
CN101675078A (zh) 2010-03-17
CL2008001238A1 (es) 2008-11-07
AU2008247958A1 (en) 2008-11-13
JP2010526076A (ja) 2010-07-29
IL201165A0 (en) 2010-05-17
CA2682835A1 (en) 2008-11-13
WO2008137338A1 (en) 2008-11-13
ZA200906812B (en) 2010-12-29
EP2152749A1 (en) 2010-02-17
US20090162356A1 (en) 2009-06-25

Similar Documents

Publication Publication Date Title
KR20100018523A (ko) ＣＲＩｇ 길항제
US8329178B2 (en) Antibodies against CXCR4 and methods of use thereof
JP2022084942A (ja) Ｃｔｌａ４に結合する抗体医薬
CN102089326B (zh) 抗白细胞介素-6/白细胞介素-6受体的抗体及其使用方法
CA2593561C (en) Combining therapies targeting multiple toll-like receptors and use thereof
JP7072576B2 (ja) 抗ｐｄ－１抗体
CN102641503A (zh) 血管生成素样4蛋白抑制剂，组合，以及其用途
CN101720232A (zh) 具有修饰的效应器功能的fc受体结合型多肽
KR20100065162A (ko) 신규한 항체
JP2015145397A (ja) 抗α２インテグリン抗体を使用する処置
KR20170138565A (ko) RGMa 결합 단백질 및 그 사용
US8197811B2 (en) Methods of use of sialoadhesin factor-2 antibodies
KR20180021136A (ko) 항-혈관 내피 성장 인자 수용체 2 (vegfr2) 항체
JP2011523359A (ja) 抗ＰｉｒＢ抗体
JP4504200B2 (ja) 抗体（“１１ｃ７”）抗ｎｏｇｏａおよびその薬学的使用
US20090285803A1 (en) ANTI-PirB ANTIBODIES
US20100047232A1 (en) Modulators of neuronal regeneration
JP2003525615A (ja) シアロアドへジンファクター−２抗体
US20260085128A1 (en) Anti-cd157 antibodies, antigen-binding fragments thereof and compositions and methods for making and using the same
WO2024020051A1 (en) Anti-cd157 antibodies, antigen-binding fragments thereof and compositions and methods for making and using the same

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20091130

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid